Neil Stahl, EVP Research and Development at REGENERON PHARMACEUTICALS INC (REGN), sold 101,000 shares at $562.37 ($56.5M) on 2015-11-06, disclosed to the SEC on 2015-11-09.
Open-market sale of $56.5M REGN by EVP Research and Development. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.00 | 1,000 | $0 | 0.0% |
| 2 | $567.63 | 935 | $531K | 0.9% |
| 3 | $567.63 | 4,047 | $2.3M | 4.1% |
| 4 | $567.63 | 13,312 | $7.6M | 13.4% |
| 5 | $567.63 | 39,605 | $22.5M | 39.8% |
| 6 | $562.37 | 9,555 |
| $5.4M |
| 9.5% |
| 7 | $563.43 | 8,345 | $4.7M | 8.3% |
| 8 | $564.19 | 2,100 | $1.2M | 2.1% |
| 9 | $558.37 | 9,694 | $5.4M | 9.6% |
| 10 | $559.26 | 1,500 | $839K | 1.5% |
| 11 | $560.31 | 3,900 | $2.2M | 3.9% |
| 12 | $561.36 | 500 | $281K | 0.5% |
| 13 | $562.31 | 5,607 | $3.2M | 5.6% |
| 14 | $563.41 | 900 | $507K | 0.9% |
| Total | $559.43 avg | 101,000 | $56.5M | 100% |
| Filing → |
| REGN | SELL | 2023-08-23 | $19.6M | — | Filing → |
| REGN | SELL | 2022-08-08 | $28.4M | — | Filing → |
| REGN | SELL | 2021-05-18 | $18.2M | — | Filing → |